首页|Advances in DNA damage response inhibitors in colorectal cancer therapy
Advances in DNA damage response inhibitors in colorectal cancer therapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
One potential cause of cancer is genomic instability that arises in normal cells due to years of DNA damage in the body.The clinical application of radiotherapy and cytotoxic drugs to treat cancer is based on the principle of damaging the DNA of cancer cells.However,the benefits of these treatments also have negative effects on normal tissue.While there have been notable advancements in molecular-driven therapy and immunotherapy for color-ectal cancer(CRC),a considerable portion of patients with advanced CRC do not experience any benefits from these treatments,leading to a poor prognosis.In recent years,targeted therapy aimed at suppressing the DNA damage response(DDR)in cancer cells has emerged as a potential treatment option for CRC patients,offering them more choices for treatment.Currently,the integration of DDR and clinical intervention remains in the exploratory phase.This review primarily elucidates the fundamental principles of DDR inhibitors,provides an overview of their current clinical application status in CRC,and discusses the advancements as well as limitations observed in relevant studies.
DNA damage responsecolorectal cancertargeted therapyDDR inhibitor
Yue Yu、Hang Jia、Tianshuai Zhang、Wei Zhang
展开 >
Department of Colorectal Surgery,the First Affiliated Hospital,Naval Medical University,Shanghai 200433,China
NETL
NSTL
万方数据
